. Taburet, Determination of amprenavir total and unbound concentrations in plasma 359 by high-performance liquid chromatography and ultrafiltration, Ther Drug Monit, vol.28, issue.2, pp.89-360, 2006.

L. Z. Benet and B. A. Hoener, Changes in plasma protein binding have little clinical relevance, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.115-136, 2002.
DOI : 10.1067/mcp.2002.121829

. Miller, Protein binding in antiretroviral therapies, AIDS Res Hum Retroviruses, vol.365, issue.4, pp.825-860, 2003.

. Csajka, Population pharmacokinetics of atazanavir in patients with human 368 immunodeficiency virus infection, Antimicrob Agents Chemother, vol.50, issue.5, pp.3801-3809, 2006.

C. B. Eap, Orosomucoid (alpha1-acid glycoprotein) plasma concentration and 371 genetic variants: effects on human immunodeficiency virus protease inhibitor clearance 372 and cellular accumulation, Clin Pharmacol Ther, vol.80, issue.6, pp.307-325, 2006.

. Influence-of-tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir 375 pharmacokinetics in HIV-infected patients Department of Health and Human Services (DHHS), and 377 http://aidsinfo.nih.gov/guidelines/, posting date. Guidelines for the use of antiretroviral 378 agents in HIV-1 infected adults and adolescents, Eur J Clin Pharmacol, vol.62, issue.7, pp.523-529

J. C. Duche, F. Herve, J. P. Tillement, M. , G. Reker et al., Study of the expression of the genetic variants of human ??1-acid glycoprotein in healthy subjects using isoelectric focusing and immunoblotting, Journal of Chromatography B: Biomedical Sciences and Applications, vol.715, issue.1, pp.103-9413, 1998.
DOI : 10.1016/S0378-4347(98)00084-X

C. B. Eap, P. Baumann, J. , S. H. Khoo, and D. J. Back, Isoelectric focusing of alpha-1 acid glycoprotein 386 (orosomucoid) in immobilized pH-gradients with 8M urea: detection of its desialylated 387 variants using an alkaline phosphatase-linked secondary antibody system Electrophoresis 388 9:650-4. 389 11 European Medicines Agency, and 390 http://www.emea.eu.int/humandocs/Humans/EPAR/reyataz/reyataz.htm, posting 391 date. [Online The intracellular pharmacology of 395 antiretroviral protease inhibitors Alpha-1-acid glycoprotein, Medjoubi, and D. Porquet, pp.982-90, 1988.

J. M. Kremer, J. Wilting, and L. H. Janssen, Drug binding to human alpha-1- 403 acid glycoprotein in health and disease, Pharmacol Rev, vol.40, issue.404, pp.1-47, 1988.

L. Tiec, C. , A. Barrail, C. Goujard, and A. M. Taburet, Clinical 405 pharmacokinetics and summary of efficacy and tolerability of atazanavir, Clin, vol.406, 2005.

S. Oie, M. A. Jacobson, and D. I. Abrams, Alpha 1-acid glycoprotein levels in 416 AIDS patients before and after short-term treatment with zidovudine (ZDV), J Acquir, p.417, 1993.

J. P. Aboulker and P. M. Girard, Interactions between atazanavir-ritonavir and 425, 2004.

J. D. Wright, F. D. Boudinot, and M. R. Ujhelyi, Measurement and Analysis of Unbound Drug Concentrations, Clinical Pharmacokinetics, vol.30, issue.6, pp.445-62, 1996.
DOI : 10.2165/00003088-199630060-00003